永盛新材料(03608.HK)有意與Bagan成立合營公司 從事東南亞水供應及污水處理項目
格隆匯3月5日丨永盛新材料(03608.HK)宣佈,於2020年3月5日,公司與Bagan訂立意向書。
根據意向書,公司及Bagan擬成立合營公司。於合營公司註冊成立後,公司及Bagan分別擁有合營公司約60%及40%。合營公司主要於東南亞從事開發、投資、營運及管理液壓系統相關項目,尤其是有關水供應及污水處理。
於於意向書訂立後,訂約方將於訂立意向書後30天內就建議合作竭力進一步磋商,以訂立正式並具法律約束力的協議。倘於訂立意向書後六個月內,訂約方並無就建議合作訂立最終及具有法律約束力的協議,則意向書將會自動失效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.